Lovenox and Skin hyperpigmentation - a phase IV clinical study of FDA data

Summary:

Skin hyperpigmentation is reported as a side effect among people who take Lovenox (enoxaparin sodium), especially for people who are female, 50-59 old, have been taking the drug for 6 - 12 months also take Magnevist, and have Nuclear magnetic resonance imaging brain.

The phase IV clinical study analyzes which people have Skin hyperpigmentation when taking Lovenox. It is created by eHealthMe based on reports of 47,547 people who have side effects when taking Lovenox from the FDA, and is updated regularly.

What is Lovenox?

Lovenox has active ingredients of enoxaparin sodium. It is often used in deep venous thrombosis. eHealthMe is studying from 48,149 Lovenox users. Check the latest studies of Lovenox.

What is Skin hyperpigmentation?

Skin hyperpigmentation (disorders affect the colour of your skin) is found to be associated with 647 drugs and 811 conditions by eHealthMe. Check the latest studies of Skin hyperpigmentation.

On Jul, 11, 2026

47,547 people reported to have side effects when taking Lovenox.
Among them, 42 people (0.09%) have Skin hyperpigmentation.

Could Lovenox cause Skin hyperpigmentation?

Among these 42 people:

How long have people been on Lovenox when they have Skin hyperpigmentation? *

What is the gender of people who have Skin hyperpigmentation when taking Lovenox? *

female: 73.17 %
male: 26.83 %

What is the age of people who have Skin hyperpigmentation when taking Lovenox? *

What are other drugs people take besides Lovenox? *

What are other side effects people have besides Skin hyperpigmentation? *

Pain: 27 people, 64.29%
Nephrogenic Systemic Fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease): 20 people, 47.62%
Skin Induration (an abnormally hard spot or area on the skin): 20 people, 47.62%
Oedema Peripheral (superficial swelling): 19 people, 45.24%
Weakness: 17 people, 40.48%
Joint Range Of Motion Decreased (disease of joint movement): 17 people, 40.48%
Rashes (redness): 17 people, 40.48%
Skin Discoloration: 17 people, 40.48%
Skin Tightness: 17 people, 40.48%
Scar: 14 people, 33.33%

What are the existing conditions these people have? *

Nuclear Magnetic Resonance Imaging Brain: 8 people, 19.05%
Vitiligo (pigment is lost from areas of the skin): 6 people, 14.29%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 6 people, 14.29%
Pain: 4 people, 9.52%
High Blood Cholesterol: 3 people, 7.14%
Multiple Myeloma (cancer of the plasma cells): 2 people, 4.76%
Acute Lymphocytic Leukaemia Recurrent (cancer in which the bone marrow makes too many lymphocytes-recurrent): 2 people, 4.76%
Sarcoma (rare cancers that develop in the muscle, bone, nerves, cartilage, tendons, blood vessels and the fatty and fibrous tissues): 2 people, 4.76%
Paroxysmal Nocturnal Haemoglobinuria (haemoglobin in the urine): 1 person, 2.38%
Nuclear Magnetic Resonance Imaging Abdominal: 1 person, 2.38%

* Approximation only. Some reports may have incomplete information.

Do you take Lovenox and have Skin hyperpigmentation?

- Check whether Skin hyperpigmentation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lovenox:

Lovenox (48,149 reports)

Browse all side effects of Lovenox:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Skin hyperpigmentation:

Skin hyperpigmentation (647 drugs)

Browse all the conditions that are associated with Skin hyperpigmentation:

Skin hyperpigmentation (811 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on enoxaparin sodium (the active ingredients of Lovenox) and Lovenox (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.